The IDA Study - Individualized blood pressure treatment: a multidisciplinary approach to uncontrolled hypertension in order to reduce morbidity and mortality
According to the World Health Organization hypertension is the most important risk factor for global morbidity and mortality. The risk implied by hypertension is reversible with a very favorable cost/benefit ratio. Yet, many patients do not achieve the desired target blood pressure of <140/90 mmHg. A major cause is that patients do not take their prescribed drugs. Internationally, there is an urgent request for more knowledge in this field. Therefore, the “Individualized blood pressure treatment: a multidisciplinary approach to uncontrolled hypertension in order to reduce morbidity and mortality” (the IDA Study) was recently run as a collaboration between the university hospitals of Oslo, Bergen, Trondheim and Tromsø.
Recruitment was terminated in 2022, and a total of 1156 patients were included. All participants underwent thorough work-up, including measurement of serum concentrations of antihypertensive drug concentrations (TDM). Participants with daytime ambulatory blood pressure >135 mmHg and low serum levels of prescribed antihypertensive drugs were classified as non-adherent and randomized to structured information based on TDM or standard care. Only 46 patients fulfilled the criteria to enter the randomized part of the study, but many relevant variables were collected for all of the participants. Also, serum and urine have been biobanked. Our group is tightly involved in several substudies based on data from the IDA study, and more studies are under planning.
The main study was funded by the Norwegian Research Council.
National study leader: Professor Morten Rostrup